These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 8515390)

  • 1. Imipramine treatment of panic disorder with agoraphobia: the second time around.
    Mavissakalian MR; Perel JM; de Groot C
    J Psychiatr Res; 1993; 27(1):61-8. PubMed ID: 8515390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imipramine treatment of panic disorder with agoraphobia: dose ranging and plasma level-response relationships.
    Mavissakalian MR; Perel JM
    Am J Psychiatry; 1995 May; 152(5):673-82. PubMed ID: 7726306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective effects of imipramine maintenance treatment in panic disorder with agoraphobia.
    Mavissakalian M; Perel JM
    Am J Psychiatry; 1992 Aug; 149(8):1053-7. PubMed ID: 1636805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2nd year maintenance and discontinuation of imipramine in panic disorder with agoraphobia.
    Mavissakalian MR; Perel JM
    Ann Clin Psychiatry; 2001 Jun; 13(2):63-7. PubMed ID: 11534926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia.
    Mavissakalian MR; Perel JM
    Arch Gen Psychiatry; 1999 Sep; 56(9):821-7. PubMed ID: 12884888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical experiments in maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia.
    Mavissakalian M; Perel JM
    Arch Gen Psychiatry; 1992 Apr; 49(4):318-23. PubMed ID: 1558466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Duration of imipramine therapy and relapse in panic disorder with agoraphobia.
    Mavissakalian MR; Perel JM
    J Clin Psychopharmacol; 2002 Jun; 22(3):294-9. PubMed ID: 12006900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A meta-analysis of treatments for panic disorder with agoraphobia: imipramine, alprazolam, and in vivo exposure.
    Cox BJ; Endler NS; Lee PS; Swinson RP
    J Behav Ther Exp Psychiatry; 1992 Sep; 23(3):175-82. PubMed ID: 1487535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imipramine dose-response relationship in panic disorder with agoraphobia. Preliminary findings.
    Mavissakalian MR; Perel JM
    Arch Gen Psychiatry; 1989 Feb; 46(2):127-31. PubMed ID: 2643933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind placebo-controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia.
    Bakish D; Hooper CL; Filteau MJ; Charbonneau Y; Fraser G; West DL; Thibaudeau C; Raine D
    Psychopharmacol Bull; 1996; 32(1):135-41. PubMed ID: 8927663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gauging the effectiveness of extended imipramine treatment for panic disorder with agoraphobia.
    Mavissakalian MR; Perel JM; Talbott-Green M; Sloan C
    Biol Psychiatry; 1998 Jun; 43(11):848-54. PubMed ID: 9611676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of a new statistical approach to evaluate a clinical trial with panic disorder patients.
    Bandelow B; Brunner E; Beinroth D; Pralle L; Broocks A; Hajak G; Rüther E
    Eur Arch Psychiatry Clin Neurosci; 1999; 249(1):21-7. PubMed ID: 10195340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluoxetine in panic disorder: pharmacologic and tritiated platelet imipramine and paroxetine binding study.
    Pecknold JC; Luthe L; Iny L; Ramdoyal D
    J Psychiatry Neurosci; 1995 May; 20(3):193-8. PubMed ID: 7786880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential combination of imipramine and self-directed exposure in the treatment of panic disorder with agoraphobia.
    Mavissakalian M
    J Clin Psychiatry; 1990 May; 51(5):184-8. PubMed ID: 2335493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific side effects of long-term imipramine management of panic disorder.
    Mavissakalian M; Perel J; Guo S
    J Clin Psychopharmacol; 2002 Apr; 22(2):155-61. PubMed ID: 11910260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A naturalistic study of imipramine in panic disorder and agoraphobia.
    Aronson TA
    Am J Psychiatry; 1987 Aug; 144(8):1014-9. PubMed ID: 3300374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imipramine for vestibular dysfunction in panic disorder: a prospective case series.
    Mezzasalma MA; Mathias Kde V; Nascimento I; Valença AM; Nardi AE
    Arq Neuropsiquiatr; 2011 Apr; 69(2A):196-201. PubMed ID: 21537560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do antidepressants selectively suppress spontaneous (unexpected) panic attacks? A replication.
    Uhlenhuth EH; Matuzas W; Warner TD; Paine S; Lydiard RB; Pollack MH
    J Clin Psychopharmacol; 2000 Dec; 20(6):622-7. PubMed ID: 11106133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imipramine in the treatment of agoraphobia: dose-response relationships.
    Mavissakalian M; Perel J
    Am J Psychiatry; 1985 Sep; 142(9):1032-6. PubMed ID: 3895987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular and symptomatic reduction effects of alprazolam and imipramine in patients with panic disorder: results of a double-blind, placebo-controlled trial.
    Taylor CB; Hayward C; King R; Ehlers A; Margraf J; Maddock R; Clark D; Roth WT; Agras WS
    J Clin Psychopharmacol; 1990 Apr; 10(2):112-8. PubMed ID: 2187912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.